A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer

被引：38

作者：

Kobayashi, Takayuki ^{[1
]}

Iwaya, Keiichi ^{[1
]}

Moriya, Tomoyuki ^{[2
]}

Yamasaki, Tamio ^{[2
]}

Tsuda, Hitoshi ^{[3
]}

Yamamoto, Junji ^{[2
]}

Matsubara, Osamu ^{[1
]}

机构：

[1] Natl Def Med Coll, Dept Basic Pathol, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan

[2] Natl Def Med Coll, Dept Surg, Tokorozawa, Saitama 3598513, Japan

[3] Natl Canc Ctr, Pathol & Clin Lab Div, Chuo Ku, Tokyo 1040045, Japan

来源：

BMC CLINICAL PATHOLOGY | 2013年 / 13卷

关键词：

Ki67 labeling index; p53; IHC panel; Luminal-type breast cancer;

D O I：

10.1186/1472-6890-13-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Ki67 is widely used in order to distinguish the "A" and "B" subtypes of luminal-type breast cancer. This study aimed to validate the prognostic value of adding p53 to Ki67 for characterizing luminal-type breast cancer. Methods: Immunostaining for Ki67, p53, and the molecular markers HER2, CK5/6, CK14, EGFR, FOXA1, GATA3, and P-cadherin was examined hormone receptor (HR)-positive cancer tissues from 150 patients. The prognostic value of an immunohistochemical panel comprising Ki67 and p53 was compared with that of the single Ki67 labeling index (LI), and uni-and multivariate analyses were performed. Results: Division of the patients based on the immunohistochemistry results into favorable-(low Ki67 LI, p53-negative) and unfavorable-(high Ki67 LI and/or p53-positive) phenotype groups yielded distinctly different Kaplan-Meier's curves of both disease-free (P<0.0001) and overall survival (P=0.0007). These differences were much more distinct than those between the corresponding low Ki67 LI vs. high Ki67LI curves. While the prognostic values of the other molecular markers were not significant, combined Ki67-p53 status was an independent prognostic factor by multivariate analysis. Conclusion: These data indicate that an immunohistochemical panel comprising Ki67 and p53 is a practical tool for management of patients with HR-positive breast cancer.

引用

页数：11

共 38 条

[1]

Badve, S., Nakshatri, H., Oestrogen-receptor-positive breast cancer: Towards bridging histopathological and molecular classifications (2009) J Clin Pathol, 62 (1), pp. 6-12. , 10.1136/jcp.2008.059899 18794199

[2]

Hortobagyi, G.N., Treatment of breast cancer (1998) New England Journal of Medicine, 339 (14), pp. 974-984. , DOI 10.1056/NEJM199810013391407

[3]

Tamoxifen for early breast cancer: An overview of the randomised trials (1998) Lancet, 351 (9114), pp. 1451-1467. , Early Breast Cancer Trialists' Collaborative Group 9605801

[4]

Mauri, D., Pavlidis, N., Polyzos, N.P., Ioannidis, J.P.A., Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis (2006) Journal of the National Cancer Institute, 98 (18), pp. 1285-1291. , DOI 10.1093/jnci/djj357

[5]

Fisher, P.B., Jeong, J.-H., Bryant, P.J., Anderson, S., Dignam, J., Fisher, P.E.R., Wolmark, P.N., Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials (2004) Lancet, 364 (9437), pp. 858-868. , DOI 10.1016/S0140-6736(04)16981-X, PII S014067360416981X

[6]

Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F.L., Wolmark, N., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer (2004) New England Journal of Medicine, 351 (27), pp. 2817-2826. , DOI 10.1056/NEJMoa041588

[7]

Cheang, M.C., Chia, S.K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Parker, J.S., Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer (2009) J Natl Cancer Inst, 101 (10), pp. 736-750. , 10.1093/jnci/djp082 19436038

[8]

Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Wolmark, N., Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer (2006) Journal of Clinical Oncology, 24 (23), pp. 3726-3734. , DOI 10.1200/JCO.2005.04.7985

[9]

Sorlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Borresen-Dale, A.-L., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications (2001) Proceedings of the National Academy of Sciences of the United States of America, 98 (19), pp. 10869-10874. , DOI 10.1073/pnas.191367098

[10]

Lacroix, M., Toillon, R.-A., Leclercq, G., P53 and breast cancer, an update (2006) Endocrine-Related Cancer, 13 (2), pp. 293-325. , DOI 10.1677/erc.1.01172

← 1 2 3 4 →